Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma
Latest Information Update: 03 Feb 2023
At a glance
- Drugs OH 2 (Primary) ; Pucotenlimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Binhui Biopharmaceutical
- 28 Jan 2023 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.
- 28 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2023.
- 18 Nov 2020 Planned End Date changed from 30 Oct 2022 to 30 Nov 2022.